Study 3: Minocycline Decreases Microglia Activation
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 1/26/2019 |
| Start Date: | July 15, 2017 |
| End Date: | May 2019 |
| Contact: | Dana Leach, DNP |
| Email: | leachdd@medicine.ufl.edu |
| Phone: | 352-273-8933 |
Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients
This study is a mechanistic study that will enroll 9 subjects who are participating in
NCT02133885 (which is designed to evaluate minocycline to test the hypothesis that
minocycline treatment would produce antihypertensive effects in drug-resistant neurogenic
hypertensive individuals) to test whether the antihypertensive effect of minocycline is
associated with a decrease in activated microglia in central nervous system autonomic regions
as evidenced by changes in PET and MRI imaging.
NCT02133885 (which is designed to evaluate minocycline to test the hypothesis that
minocycline treatment would produce antihypertensive effects in drug-resistant neurogenic
hypertensive individuals) to test whether the antihypertensive effect of minocycline is
associated with a decrease in activated microglia in central nervous system autonomic regions
as evidenced by changes in PET and MRI imaging.
This study will recruit 9 subjects from NCT02133885 who will agree to undergo additional
autonomic testing and imaging studies at baseline and after 3-6 months of study treatment.
Specialized imaging of the brain using magnetic resonance imaging (MRI) and positron emission
tomography (PET) scanning will be conducted at the Montreal Neurological Institute, in
Montreal Canada.
autonomic testing and imaging studies at baseline and after 3-6 months of study treatment.
Specialized imaging of the brain using magnetic resonance imaging (MRI) and positron emission
tomography (PET) scanning will be conducted at the Montreal Neurological Institute, in
Montreal Canada.
Inclusion Criteria:
- Subjects participating in IRB approved protocol #102-2013 will be eligible to
participate.
Exclusion criteria for control and resistant hypertensive subjects include:
- currently pregnant or have been pregnant in the last 6 months;
- antibiotic treatment within 2 months of study enrollment;
- currently taking a medication (e.g., antibiotic, anti-inflammatory agents,
glucocorticoids or other immune modulating medications);
- unwilling to discontinue vitamin or supplements, including probiotics, potentially
affecting gut microbiota (vitamins/supplements and medications that possibly affect
the gut microbiota should be discontinued for at least 2wks prior to stool
collection);
- history of intestinal surgery, inflammatory bowel disease, celiac disease, lactose
intolerance, chronic pancreatitis or other malabsorption disorder.
We found this trial at
1
site
Click here to add this to my saved trials
